AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33500258 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitors (treatment duration: median 11.1 months)
Number of subjects: 52
Study 32083290 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant S1 therapy
Number of subjects: 0
Study 32083290 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX regimen as adjuvant therapy
Number of subjects: 0
Study 32083290 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 36165504 — intervention group
Group type: EXPERIMENTAL
Intervention: LAVA TQ
Number of subjects: 144
Study 36165504 — intervention group
Group type: COMPARATOR
Intervention: CAT
Number of subjects: 144
Study 33591032 — intervention group
Group type: EXPERIMENTAL
Intervention: ADASCs alone (3 × 10⁶ cells/1 mL) in Group 1 (n = 5)
Number of subjects: 14
Study 33591032 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-μm decellularized corneal stroma lamina in Group 2 (n = 5)
Number of subjects: 14
Study 33591032 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-μm lamina recellularized with ADASCs (1 × 10⁶ cells/1 mL) in Group 3 (n = 4)
Number of subjects: 14
Study 32468892 — intervention group
Group type: EXPERIMENTAL
Intervention: SB4, SB2, and SB5 (biosimilars of ETN, INF, and ADA)
Number of subjects: 1709
Study 32468892 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilars combined (SB4, SB2, SB5)
Number of subjects: 1709
Study 32468892 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference products combined (ETN, INF, ADA)
Number of subjects: 1709
Study 32468892 — intervention group
Group type: EXPERIMENTAL
Intervention: All-treatments-combined
Number of subjects: 1709
Study 32468892 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2 + INF
Number of subjects: 1709
Study 34271931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural beliefs on breastfeeding cessation
Number of subjects: 55
Study 34271931 — intervention group
Group type: EXPERIMENTAL
Intervention: Local explanatory model of child diarrhoea
Number of subjects: 55
Study 34271931 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of diarrhoea treatment
Number of subjects: 55
Study 34271931 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of local explanatory model in healthcare
Number of subjects: 55
Study 35462408 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment
Number of subjects: 0
Study 35462408 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment based on patient goals and values
Number of subjects: 0
Study 33915252 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 185
Study 33915252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 33317375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1031
Study 33317375 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 1031
Study 33317375 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehypertension
Number of subjects: 1031
Study 35906004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure
Number of subjects: 0
Study 33410583 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0
Study 33410583 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study 34591549 — intervention group
Group type: EXPERIMENTAL
Intervention: panic‐focused psychodynamic psychotherapy (PFPP)
Number of subjects: 217
Study 34591549 — intervention group
Group type: COMPARATOR
Intervention: panic control treatment (PCT)
Number of subjects: 217
Study 35477633 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM5 (5 mg)
Number of subjects: 949
Study 35477633 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM10 (10 mg)
Number of subjects: 949
Study 35477633 — intervention group
Group type: COMPARATOR
Intervention: PBO (placebo)
Number of subjects: 949
Study 35770861 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient treatment
Number of subjects: 126
Study 35770861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 35123779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐flunixin group (1‐FLU, n = 26) with a single administration of transdermal flunixin meglumine at disbudding
Number of subjects: 71
Study 35123779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐flunin group (2‐FLU, n = 24) with 2 administrations of transdermal flunixin meglumine, the first treatment at disbudding and the second 6 h after disbudding
Number of subjects: 71
Study 35123779 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n = 27) received a placebo
Number of subjects: 71
Study 35123779 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1‐FLU, 2‐FLU, CON)
Number of subjects: 71
Study 34675472 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.1% ophthalmic solution, administered once daily for 14–84 days
Number of subjects: 568
Study 34675472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle), administered once daily for 14–84 days
Number of subjects: 568
Study 34675472 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.1% ophthalmic solution
Number of subjects: 568
Study 34675472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 568
Study 33148672 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy after breast-conserving surgery (BCS)
Number of subjects: 0
Study 33148672 — intervention group
Group type: COMPARATOR
Intervention: Breast-conserving surgery (BCS) only
Number of subjects: 0
Study 32599131 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to abdominal area (treatment group A)
Number of subjects: 3
Study 32599131 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to upper arms/shoulders (treatment group B)
Number of subjects: 3
Study 32599131 — intervention group
Group type: EXPERIMENTAL
Intervention: IVPT method using FTC diffusion system, SM membrane, and phosphate buffer without surfactant
Number of subjects: 3
Study 35774276 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of sweet almond oil (126 ml over 7 sessions in 2 weeks, 18 ml every other day)
Number of subjects: 90
Study 35774276 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage with sweet almond oil (same amount as oral group, during 7 sessions in 2 weeks)
Number of subjects: 90
Study 35774276 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 90
Study 35774276 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of sweet almond oil
Number of subjects: 90
Study 35774276 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 90
Study 33974129 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 µg/d iodine
Number of subjects: 122
Study 33974129 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 µg/d iodine
Number of subjects: 122
Study 33974129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 34034960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast adaptation (10 h wear from the first day)
Number of subjects: 74
Study 34034960 — intervention group
Group type: COMPARATOR
Intervention: Gradual adaptation (4 h on the first day, increasing by 2 h daily until 10 h)
Number of subjects: 74
Study 34099007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity psychosocial telemental interventions
Number of subjects: 58
Study 34099007 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 33788479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Tiaowei
Number of subjects: 90
Study 33788479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Yangxin
Number of subjects: 90
Study 33788479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Tiaozang
Number of subjects: 90
Study 35002557 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Budesonide (BUD) 2 mL, 0.25‐mg/mL suspension, inhalation, twice daily for 5 days
Number of subjects: 120
Study 35002557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (humidified distilled sterile water inhalation, 2 mL)
Number of subjects: 120
Study 36401514 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group (37 patients)
Number of subjects: 72
Study 36401514 — intervention group
Group type: COMPARATOR
Intervention: Unstented group (35 patients)
Number of subjects: 72
Study 34452681 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy Team (BTT) intervention consisting of individual information-gathering sessions followed by 12 weeks of group ERP and concurrent home-based coaching sessions
Number of subjects: 47
Study 34452681 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy Team (BTT) intervention
Number of subjects: 47
Study 34452681 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 47
Study 32744578 — intervention group
Group type: EXPERIMENTAL
Intervention: ET followed by RT (E+R; n=10)
Number of subjects: 30
Study 32744578 — intervention group
Group type: EXPERIMENTAL
Intervention: RT followed by ET (R+E; n=10)
Number of subjects: 30
Study 32744578 — intervention group
Group type: COMPARATOR
Intervention: Control (C; n=10)
Number of subjects: 30
Study 36175919 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS + WMT
Number of subjects: 120
Study 36175919 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS + simple response training (SRT)
Number of subjects: 120
Study 36175919 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS + WMT
Number of subjects: 120
Study 36175919 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS + SRT
Number of subjects: 120
Study 32551958 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 84
Study 32551958 — intervention group
Group type: COMPARATOR
Intervention: Conventional recovery after surgery (Control)
Number of subjects: 84
Study 35974157 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation with PEEP 8 cmH2O (No-RM), n = 12
Number of subjects: 68
Study 35974157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflation (SI), n = 15
Number of subjects: 68
Study 35974157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic PEEP strategy (maximum PEEP 14 or 20 cmH2O), n = 41
Number of subjects: 68
Study 35974157 — intervention group
Group type: COMPARATOR
Intervention: All strategies (No-RM, SI, DynPEEP)
Number of subjects: 68
Study 33464316 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 4109
Study 33464316 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 4109
Study 33464316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 4109
Study 33464316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4109
Study 32372186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri LR92 DSM 26866 (1 × 10^8 CFU daily for 4 weeks)
Number of subjects: 145
Study 32372186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (9% glucose solution for 4 weeks)
Number of subjects: 145
Study 32372186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri LR92 DSM 26866
Number of subjects: 145
Study 33198432 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aid (educational visual aid provided prior to simulation)
Number of subjects: 44
Study 33198432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visual aid provided)
Number of subjects: 44
Study 33230190 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT, n = 21)
Number of subjects: 42
Study 33230190 — intervention group
Group type: COMPARATOR
Intervention: Computer games (TAU, n = 21)
Number of subjects: 42
Study 37313689 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 48
Study 37313689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 34229284 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS stimulation
Number of subjects: 50
Study 34229284 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 50
Study 32958483 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-targeted and GP-targeted feedback regarding the depression screening results
Number of subjects: 1074
Study 32958483 — intervention group
Group type: COMPARATOR
Intervention: Only GP-targeted feedback
Number of subjects: 1074
Study 32958483 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 1074
Study 35850078 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth environment room
Number of subjects: 680
Study 35850078 — intervention group
Group type: COMPARATOR
Intervention: Standard birth room
Number of subjects: 680
Study 33763126 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological music therapy
Number of subjects: 40
Study 34001205 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-articular liposomal bupivacaine plus bupivacaine hydrochloride
Number of subjects: 0
Study 34001205 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride alone
Number of subjects: 0
Study 36063826 — intervention group
Group type: EXPERIMENTAL
Intervention: EV 4 mg/d
Number of subjects: 88
Study 36063826 — intervention group
Group type: EXPERIMENTAL
Intervention: EV 6 mg/d
Number of subjects: 88
Study 36063826 — intervention group
Group type: EXPERIMENTAL
Intervention: EV 9 mg/d
Number of subjects: 88
Study 33641238 — intervention group
Group type: EXPERIMENTAL
Intervention: PR‐Tac with continental breakfast
Number of subjects: 36
Study 33641238 — intervention group
Group type: EXPERIMENTAL
Intervention: IR‐Tac with continental breakfast
Number of subjects: 36
Study 35635201 — intervention group
Group type: COMPARATOR
Intervention: Daily application of negatively charged polystyrene microspheres (NCMs)
Number of subjects: 30
Study 35635201 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of negatively charged polystyrene microspheres (NCMs) three times per week
Number of subjects: 30
Study 33358539 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 125
Study 33358539 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Number of subjects: 125
Study 33358539 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study 32819529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 0
Study 35042096 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 426
Study 35042096 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 426
Study 35042096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 34861869 — intervention group
Group type: EXPERIMENTAL
Intervention: Support provided to participants during the trial
Number of subjects: 20
Study 34861869 — intervention group
Group type: EXPERIMENTAL
Intervention: Addressing participants' concerns and ethical issues
Number of subjects: 20
Study 34861869 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymous concerns reported to the trial team
Number of subjects: 20
Study 34861869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical strategies employed
Number of subjects: 20
Study 35079762 — intervention group
Group type: EXPERIMENTAL
Intervention: sbeII wheat bread
Number of subjects: 19
Study 35079762 — intervention group
Group type: COMPARATOR
Intervention: WT control bread
Number of subjects: 19
Study 33198634 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred deprescribing intervention (2-hour training of PCPs, use of a validated deprescribing algorithm, shared decision-making)
Number of subjects: 334
Study 33198634 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 334
Study 33198634 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred deprescribing intervention
Number of subjects: 334
Study 34915659 — intervention group
Group type: EXPERIMENTAL
Intervention: Semilunar-tunnel flap technique (SLTT)
Number of subjects: 20
Study 34915659 — intervention group
Group type: COMPARATOR
Intervention: Modified papilla preserved technique (MPPT)
Number of subjects: 20
Study 32171252 — intervention group
Group type: EXPERIMENTAL
Intervention: Network-offered training programs focusing on best practice guideline-oriented use of antibiotics
Number of subjects: 45
Study 32171252 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer communication within primary care networks
Number of subjects: 45
Study 32171252 — intervention group
Group type: EXPERIMENTAL
Intervention: Social influence processes
Number of subjects: 45
Study 32171252 — intervention group
Group type: EXPERIMENTAL
Intervention: ARena intervention components
Number of subjects: 45
Study 32171252 — intervention group
Group type: EXPERIMENTAL
Intervention: Network peer exchange
Number of subjects: 45
Study 32171252 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations from stakeholders regarding networks
Number of subjects: 45
Study 36171184 — intervention group
Group type: EXPERIMENTAL
Intervention: EXERCISE (n = 25), 4 months·yr ‐1 for 5 years
Number of subjects: 64
Study 36171184 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (n = 26)
Number of subjects: 64
Study 33475727 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids (EAA) supplementation (n = 28)
Number of subjects: 92
Study 33475727 — intervention group
Group type: COMPARATOR
Intervention: Whey protein supplementation (n = 32)
Number of subjects: 92
Study 33475727 — intervention group
Group type: COMPARATOR
Intervention: Control group (nutrition education, n = 32)
Number of subjects: 92
Study 32886426 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP = 8 cmH2O
Number of subjects: 118
Study 32886426 — intervention group
Group type: EXPERIMENTAL
Intervention: pH < 7.2
Number of subjects: 118
Study 32886426 — intervention group
Group type: EXPERIMENTAL
Intervention: pCO2 > 70 mmHg
Number of subjects: 118
Study 32886426 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 > 40%
Number of subjects: 118
Study 32886426 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest retractions
Number of subjects: 118
Study 32886426 — intervention group
Group type: EXPERIMENTAL
Intervention: More than two episodes of apnea requiring intervention
Number of subjects: 118
Study 32886426 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest X-ray showing moderate–severe hyaline membrane disease (HMD)
Number of subjects: 118
Study 35941669 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin once daily for 28 days
Number of subjects: 220
Study 35941669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 32658020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous screw (CS) fixation with a 3-screw inverted triangle pattern
Number of subjects: 898
Study 32658020 — intervention group
Group type: COMPARATOR
Intervention: Cancellous screw (CS) fixation with a 3-screw triangle formation
Number of subjects: 898
Study 32658020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) fixation
Number of subjects: 898
Study 32658020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous screw (CS) and sliding hip screw (SHS) technical factors
Number of subjects: 898
Study 33361038 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized educational and psychological counseling (SEPC)
Number of subjects: 60
Study 33361038 — intervention group
Group type: COMPARATOR
Intervention: Current medical practice (Control)
Number of subjects: 60
Study 32895226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 1.5 mg bolus given every 10 min until NRS pain score <4
Number of subjects: 140
Study 32895226 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus morphine 0.05 mg/kg body weight followed by 0.025 mg/kg/hour intravenous infusion
Number of subjects: 140
Study 33400384 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy-based care program (RTCP)
Number of subjects: 192
Study 33400384 — intervention group
Group type: COMPARATOR
Intervention: Control care program (CCP)
Number of subjects: 192
Study 32948550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling method (n=217)
Number of subjects: 578
Study 32948550 — intervention group
Group type: COMPARATOR
Intervention: Volunteering method (n=361)
Number of subjects: 578
Study 32948550 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status assessment
Number of subjects: 578
Study 32948550 — intervention group
Group type: EXPERIMENTAL
Intervention: Health needs assessment
Number of subjects: 578
Study 35638971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval exercise in normoxia (FIO2 = 0.209)
Number of subjects: 25
Study 35638971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval exercise in hypoxia (FIO2 = 0.112)
Number of subjects: 25
Study 35638971 — intervention group
Group type: COMPARATOR
Intervention: Resting (control) in normoxia (FIO2 = 0.209)
Number of subjects: 25
Study 35638971 — intervention group
Group type: COMPARATOR
Intervention: Resting (control) in hypoxia (FIO2 = 0.112)
Number of subjects: 25
Study 34770188 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based workshops utilizing a social norms-based mental health-integrated approach
Number of subjects: 148
Study 34770188 — intervention group
Group type: COMPARATOR
Intervention: Poster campaigns addressing IPV
Number of subjects: 148
Study 35942458 — intervention group
Group type: EXPERIMENTAL
Intervention: PDCA model education and training for midwives
Number of subjects: 0
Study 35942458 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing mode
Number of subjects: 0
Study 33761970 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib alone
Number of subjects: 46
Study 33761970 — intervention group
Group type: EXPERIMENTAL
Intervention: RB1 gene expression analysis on CTCs
Number of subjects: 46
Study 32617881 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG injection 36 hours before oocyte retrieval
Number of subjects: 172
Study 32617881 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) injection 36 hours before oocyte retrieval
Number of subjects: 172
Study 32617881 — intervention group
Group type: COMPARATOR
Intervention: No injection 36 hours before oocyte retrieval
Number of subjects: 172